BETA Technologies launches IPO of 25 million shares priced $27-$33
Ionis Pharmaceuticals (NASDAQ:IONS) Executive Vice President and CFO Elizabeth L. Hougen sold 49,800 shares of common stock on September 30, 2025, for approximately $3.25 million. The shares were sold at a weighted average price of $65.2557, with individual sales prices ranging from $65.00 to $65.52. The transaction comes as the stock trades near its 52-week high of $65.55, having delivered an impressive return of 140% over the past six months. InvestingPro analysis suggests the stock is currently in overbought territory.
According to a Form 4 filing with the Securities and Exchange Commission, the sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on January 13, 2024.
On the same day, Hougen also exercised options to acquire 49,800 shares of Ionis Pharmaceuticals common stock at an exercise price of $53.77, for a total value of $2.68 million.
Following these transactions, Hougen directly owns 110,500 shares of Ionis Pharmaceuticals.
In other recent news, Ionis Pharmaceuticals has reported several significant developments. Goldman Sachs upgraded Ionis Pharmaceuticals from Sell to Neutral, highlighting the company’s pipeline potential, particularly its antisense oligonucleotide technology. The upgrade was influenced by positive Phase 3 data for Tryngolza in treating severe hypertriglyceridemia, with peak sales estimated at $1.7 billion upon its expected launch in the fourth quarter of 2026. Additionally, Leerink Partners raised its price target for Ionis Pharmaceuticals to $68.00, maintaining an Outperform rating, following promising topline results for zilganersen, a treatment for the ultra-rare Alexander disease.
Guggenheim also increased its price target for Ionis Pharmaceuticals to $92.00, maintaining a Buy rating, due to positive Phase 3 trial data for the same treatment. H.C. Wainwright reiterated its Buy rating with a $95.00 price target, emphasizing zilganersen’s disease-modifying benefits in Alexander disease, including a 33% improvement in gait speed and a favorable safety profile. The company announced that zilganersen demonstrated statistically significant stabilization in gait speed, with consistent benefits across key secondary endpoints, suggesting potential to slow disease progression. These developments reflect Ionis Pharmaceuticals’ ongoing advancements in addressing rare neurological disorders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.